ASAM eLearning
Treatment of Opioid Use Disorder: Waiver Qualifying - New Orleans, LA - Friday, September 27, 2019
Host: AmeriHealth Caritas
Friday, September 27, 2019 | 8:00 am - 5:00 pm
Location:
AmeriHealth Caritas Louisiana Community Wellness Center
3155 Gentilly Boulevard
New Orleans, LA 70122
Cost: $199
Welcome to the ASAM Treatment of Opioid Use Disorder Course. Please LOG IN to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.
This 8-hour live course covers all treatments and medications for opioid use disorder, and is designed for licensed physician assistants, nurse practitioners, and physicians who plan to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.
Overview of Legislation
Physician Assistants & Nurse Practitioners
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat opioid use disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver.
This training is divided into two parts of 8 hours and 16 hours. This 8 hour course will satisfy Part 1 and Part 2 can be completed online for free.
For NPs (CE Credit through AANP): Click Here
For PAs (AAPA Category 1 CME Credit): Click Here
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Click here to view additional resources.
Upon completion of the live course, you will be able to claim CME Credit through the ASAM e-Learning Center after completing the evaluation module.
CME Information and Disclosure Listing
Date of Release: July 2015
Approved Through: December 2019
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM Treatment of Opioid Use Disorder Course Program Planning Committee
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Dan Alford, MD, MPH, DFASAM, Chair | None | ||
Paula J. Lum, MD, MPH, FASAM, Vice Chair | None | ||
Edwin Salsitz, MD, DFASAM, Curriculum Director | None | ||
Soraya Azari, MD | None | ||
Jill Mattingly, DHSc, MMSc, PA-C | None | ||
Debra Newman, PA-C, MPAS, MPH | None | ||
| Mary McMasters, MD, DFASAM | None | ||
Yngvild K. Olsen, MD, MPH, DFASAM | None | ||
| Shawn Ryan, MD, MBA, FASAM | Adapt Pharma Orexo | Consulting Fee Honorarium | Content Expert Speaker |
| Kristin Smith, DNP, FNP-C, AAHIVS | None | ||
| Tricia E. Wright, MD, MS, FACOG, FASAM | None | ||
ASAM CME Committee
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
| Catherine Friedman, MD, FAPA, DFASAM, Chair | None | ||
| R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM | None | ||
| Adam J. Gordon, MD, MPH, FACP, DFASAM | None | ||
| Zwaantje Hamming, FNP-C, CARN-AP | None | ||
Herbert L. Malinoff, MD, FACP, DFASAM | None | ||
Noel Ilogu, MD, MRCP, DFASAM | None | ||
Edwin A. Salsitz, MD, DFASAM | None | ||
ASAM Staff and Consultants | |||
| Arlene C. Deverman, MA, CAE, CFRE | None | ||
Marcia Jackson, PhD | None | ||
| Sandy Metcalfe | None | ||
ASAM Medical Education Council
Name | Nature of Relevant Financial Relationship | |||
Commercial Interest | What was received? | For what role? | ||
Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair | Pfizer
Johnson & Johnson Pfizer Canada | Grant funding Consulting Fees Consulting Fees | Principal Investigator Consulting Consulting | |
| Daniel P. Alford, MD, MPH, DFASAM | None | |||
| Michael Fingerhood, MD, FACP, FASAM | None | |||
| Catherine R. Friedman, MD, FAPA, DFASAM | None | |||
| Adam J. Gordon, MD, MPH, FACP, DFASAM | None | |||
| Miriam S. Komaromy, MD, FACP, DFASAM | None | |||
| Edwin A. Salsitz, MD, DFASAM | None | |||
| Mark P. Schwartz, MD, DFASAM | None | |||
| Mark A. Weiner, MD, FASAM | None | |||
| ASAM Staff and Consultants | ||||
| Penny S. Mills, MBA | None | |||
| Arlene C. Deverman, MA, CAE, CFRE | None | |||
| Marcia Jackson, PhD | None | |||
| Dawn C. Howell | None | |||
| Molly S. Mazuk | None | |||
| Alexandra (Alli) Unger | None | |||
| Jennifer L. Butchart | None | |||
At the conclusion of this activity, learners should be able to:
- Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
- Identify and assess patients who are appropriate for treatment with medications
- Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
- Discuss the psychiatric and medical co-morbidities associated with opioid addiction
Licensed physicians, nurse practitioners, and physician assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
- Fill out the survey by clicking the “Fill out Survey” button in the box titled “The ASAM Treatment of Opioid Use Disorder Course Live Portion Evaluation” at the end of the training.
- Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window
- Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window
- Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
- Click the button “Claim Medical Credits” in the box titled “CME Certificate”
- Choose the type of credit (Physician or Non-physician) and click submit
- Click the button “View/Print Certificate” to save or print your certificate
- Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)
Apply
NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.
NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.gov or fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.
SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.
Click here for more information on applying for a waiver to prescribe buprenorphine.
Key:
Complete
Next
Failed
Available
LockedThe ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.
